CardioFocus kicks off EU atrial fibrillation trial

CardioFocus is launching a multi-center trial in Europe, testing its HeartLight balloon-based ablation system on 150 patients with drug-refractory, persistent atrial fibrillation. The study will test CardioFocus' device against standard radiofrequency ablation, completing enrollment by next May and planning a one-year follow-up. Meanwhile, CardioFocus is in the midst of a U.S. trial for FDA approval, aiming to wrap up enrollment this year. More

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.